146 related articles for article (PubMed ID: 15947684)
1. Vascular endothelial growth factor antisense pretreatment of bladder cancer cells significantly enhances the cytotoxicity of mitomycin C, gemcitabine and Cisplatin.
Krause S; Förster Y; Kraemer K; Fuessel S; Kotzsch M; Schmidt U; Wirth MP; Meye A; Schwenzer B
J Urol; 2005 Jul; 174(1):328-31. PubMed ID: 15947684
[TBL] [Abstract][Full Text] [Related]
2. Chemosensitization of bladder cancer cell lines by human telomerase reverse transcriptase antisense treatment.
Kraemer K; Fuessel S; Kotzsch M; Ning S; Schmidt U; Wirth MP; Meye A
J Urol; 2004 Nov; 172(5 Pt 1):2023-8. PubMed ID: 15540782
[TBL] [Abstract][Full Text] [Related]
3. Optimizing chemotherapy for transitional cell carcinoma by application of bcl-2 and bcl-xL antisense oligodeoxynucleotides.
Bolenz C; Becker A; Trojan L; Schaaf A; Cao Y; Weiss C; Alken P; Michel MS
Urol Oncol; 2007; 25(6):476-82. PubMed ID: 18047955
[TBL] [Abstract][Full Text] [Related]
4. 1,25D3 enhances antitumor activity of gemcitabine and cisplatin in human bladder cancer models.
Ma Y; Yu WD; Trump DL; Johnson CS
Cancer; 2010 Jul; 116(13):3294-303. PubMed ID: 20564622
[TBL] [Abstract][Full Text] [Related]
5. Effect of hyperthermia on the cytotoxicity of 4 chemotherapeutic agents currently used for the treatment of transitional cell carcinoma of the bladder: an in vitro study.
van der Heijden AG; Verhaegh G; Jansen CF; Schalken JA; Witjes JA
J Urol; 2005 Apr; 173(4):1375-80. PubMed ID: 15758808
[TBL] [Abstract][Full Text] [Related]
6. Editorial comment on: Long-term survival after gemcitabine and cisplatin in patients with locally advanced transitional cell carcinoma of the bladder: focus on supplementary treatment strategies.
Gschwend JE
Eur Urol; 2007 Aug; 52(2):486-7. PubMed ID: 17383081
[No Abstract] [Full Text] [Related]
7. Gemcitabine for unresectable, locally advanced or metastatic bladder cancer.
Shelley M; Cleves A; Wilt TJ; Mason M
Cochrane Database Syst Rev; 2011 Apr; (4):CD008976. PubMed ID: 21491413
[TBL] [Abstract][Full Text] [Related]
8. A Phase I Trial of Intravesical Cabazitaxel, Gemcitabine and Cisplatin for the Treatment of Nonmuscle Invasive bacillus Calmette-Guérin Unresponsive or Recurrent/Relapsing Urothelial Carcinoma of the Bladder.
DeCastro GJ; Sui W; Pak JS; Lee SM; Holder D; Kates MM; Virk RK; Drake CG; Anderson CB; James B; Abate-Shen CT; McKiernan JM
J Urol; 2020 Aug; 204(2):247-253. PubMed ID: 32118506
[TBL] [Abstract][Full Text] [Related]
9. Lymphoepithelioma-Like Bladder Carcinoma: A Diagnostic and Therapeutic Challenge. Contribution Using a New Case and Review of the Literature.
Rodríguez-Cabello MA; Méndez-Rubio S; Sanz-Miguelañez JL; Saenz-Medina J; Garrido-Abad P; Del-Barrio-Díaz-Aldagalan A; López-Elzaurdia C; Platas-Sancho A
Clin Genitourin Cancer; 2017 Jun; 15(3):e507-e515. PubMed ID: 28139445
[No Abstract] [Full Text] [Related]
10. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer.
Galsky MD; Pal SK; Chowdhury S; Harshman LC; Crabb SJ; Wong YN; Yu EY; Powles T; Moshier EL; Ladoire S; Hussain SA; Agarwal N; Vaishampayan UN; Recine F; Berthold D; Necchi A; Theodore C; Milowsky MI; Bellmunt J; Rosenberg JE;
Cancer; 2015 Aug; 121(15):2586-93. PubMed ID: 25872978
[TBL] [Abstract][Full Text] [Related]
11. Re: Phase II trial of neoadjuvant gemcitabine and cisplatin in patients with resectable bladder carcinoma.
Sherif A
Int Braz J Urol; 2007; 33(6):840-1. PubMed ID: 18199355
[No Abstract] [Full Text] [Related]
12. Palliative chemotherapy with gemcitabine, paclitaxel, and cisplatin as first-line treatment following gemcitabine monotherapy for patients with transitional cell carcinoma of the urothelium.
Ecke TH; Gerullis H; Bartel P; Koch S; Ruttloff J
Minerva Urol Nefrol; 2009 Mar; 61(1):1-8. PubMed ID: 19417721
[TBL] [Abstract][Full Text] [Related]
13. Long-term survival after gemcitabine and cisplatin in patients with locally advanced transitional cell carcinoma of the bladder: focus on supplementary treatment strategies.
Als AB; Sengelov L; von der Maase H
Eur Urol; 2007 Aug; 52(2):478-86. PubMed ID: 17383078
[TBL] [Abstract][Full Text] [Related]
14. Gemcitabine in bladder cancer.
Sternberg CN
Semin Oncol; 2000 Feb; 27(1 Suppl 2):31-9. PubMed ID: 10697034
[TBL] [Abstract][Full Text] [Related]
15. Gemcitabine and radiotherapy plus cisplatin after transurethral resection as conservative treatment for infiltrating bladder cancer: Long-term cumulative results of 2 prospective single-institution studies.
Caffo O; Fellin G; Graffer U; Mussari S; Tomio L; Galligioni E
Cancer; 2011 Mar; 117(6):1190-6. PubMed ID: 20960501
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant Chemotherapy With Gemcitabine and Cisplatin for Plasmacytoid Urothelial Bladder Cancer: A Case Report and Review of the Literature.
Gunaratne DA; Krieger LE; Maclean F; Vaux KJ; Chalasani V
Clin Genitourin Cancer; 2016 Feb; 14(1):e103-5. PubMed ID: 26431887
[No Abstract] [Full Text] [Related]
17. Impact of Gemcitabine and Cisplatin with radiotherapy in locally advanced or metastatic transitional cell carcinoma of urinary bladder.
Mallick JA; Ali SA; Siddiqui N; Fareed A
J Pak Med Assoc; 2003 Nov; 53(11):547-52. PubMed ID: 14738263
[TBL] [Abstract][Full Text] [Related]
18. Regression of choroidal neovascularization in response to systemic chemotherapy for cancer.
Hsu AW; Sodhi A; Eberhart C; Montaner S; Goldberg MF
Can J Ophthalmol; 2013 Aug; 48(4):e80-2. PubMed ID: 23931490
[No Abstract] [Full Text] [Related]
19. Expression of nucleoside transporters and deoxycytidine kinase proteins in muscle invasive urothelial carcinoma of the bladder: correlation with pathological response to neoadjuvant platinum/gemcitabine combination chemotherapy.
North S; El-Gehani F; Santos C; Ghosh S; Lai R; Cass CE; Mackey JR
J Urol; 2014 Jan; 191(1):35-9. PubMed ID: 23851183
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy.
Sternberg CN; Calabrò F; Pizzocaro G; Marini L; Schnetzer S; Sella A
Cancer; 2001 Dec; 92(12):2993-8. PubMed ID: 11753976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
